Compare Colgate-Palmolive Company (CL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Colgate-Palmolive Company vs State Street SPDR S&P Biotech ETF — how do they compare? Colgate-Palmolive Company trades at $91.75 (market cap $72.84B), while State Street SPDR S&P Biotech ETF trades at $156.1. The key difference: Colgate-Palmolive Company pays a 2.33% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Colgate-Palmolive Company nearer its low. Which is the better fit depends on your goals.
| CL | XBI | |
|---|---|---|
Market Cap | $72.84B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $99.14 | $164.28 |
52-Week Low | $74.98 | $85.16 |
Enterprise Value | $79.48B | — |
Dividend Yield | 2.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Colgate-Palmolive (CL) trades at $93.21, up 1.05% with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with 60.06% gross margins and 822.05% ROE, though valuation metrics appear elevated with a P/E of 36.13. Recent dividend declarations and positive analyst coverage (42% buy rating) support the defensive stock's appeal amid market rotation into stable cash flow names.
Outlook remains positive with a $97 consensus price target representing 4% upside, though premium valuation and North American segment softness present headwinds. The company's 64-year dividend growth streak and global diversification provide stability, while inflation pressures and competitive threats require monitoring for sustained outperformance.
XBI trades at $155.34, down 2.32% on the day, but maintains a bullish technical outlook with strong momentum indicators. The biotech ETF has gained significant attention after a 17% monthly surge, driven by sector rotation and M&A activity. Analyst coverage remains limited with a single hold rating, though recent news highlights biotech's strong performance amid market volatility.
The ETF offers exposure to biotech's resurgence with AI drug discovery and deal momentum as catalysts. However, high volatility and concentrated sector risk require careful position sizing. Current technical strength suggests potential for continued upside if sector momentum persists.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Colgate-Palmolive Company
Since its founding in 1806, Colgate-Palmolive has grown to become a leading global consumer product company. In addition to its namesake oral care line, the firm manufactures shampoos, shower gels, deodorants, and home care products that are sold in over 200 countries (international sales account for about 70% of its consolidated total, including approximately 45% from emerging regions). It also owns specialty pet food maker Hill's, which sells its products through veterinarians and specialty pet retailers.
Read more on CL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
